REVIEW ARTICLES
ORIGINAL ARTICLES
Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial
F. Sawano, N. Kamei, M. Miyahara, K. Kobuke, S. Nakanishi, C. Nagano, H. Nojima, S. Maeda, H. Watanabe, R. Kishimoto, M. Yamashita, A. Hamaoka, K. Mukai, T. Tsuboi, H. Mochizuki, R. Nakashima, Y. Sakashita, H. Morishita, T. Kitamura 364-378
Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro
L. Yamamoto, S. Yamashita, T. Nomiyama, T. Kawanami, Y. Hamaguchi, T. Shigeoka, T. Horikawa, Y. Tanaka, T. Yanase, D. Kawanami, A. Iwasaki 389-398
CASE REPORTS
Clinical features resembling subcutaneous insulin resistance observed in a patient with type 2 diabetes and severe COVID-19-associated pneumonia: a case report
A. Satomura, Y. Oikawa, S. Nakanishi, S. Takagi, G. Mizutani, S. Iida, H. Nakayama, Y. Haga, M. Nagata, S. Maesaki, T. Mimura, A. Shimada 474-479